A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

NCT05841238 · Completed

Last updated 2026-05-28

This clinical trial tests the effects of the investigational drug LY3502970 in healthy adults who are overweight or obese to understand how the drug is absorbed and processed by the body.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 52 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2023-04 · est. completion 2023-11

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT05841238 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.

Treatments tested

LY3502970 Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970
Sponsor	Eli Lilly and Company
Conditions studied	Healthy, Obese
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05841238 ↗